Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled studyReport as inadecuate




Indacaterol improves lung hyperinflation and physical activity in patients with moderate chronic obstructive pulmonary disease - a randomized, multicenter, double-blind, placebo-controlled study - Download this document for free, or read online. Document in PDF available to download.

BMC Pulmonary Medicine

, 14:158

COPD and occupational lung disease

Abstract

BackgroundIndacaterol is a long-acting beta-2 agonist for once-daily treatment of COPD. We evaluated the effects of indacaterol 150 μg on lung hyperinflation compared with placebo and open-label tiotropium 18 μg. We measured physical activity during treatment with indacaterol 150 μg and matched placebo.

MethodsWe performed a randomized, three-period, cross-over study 21 days of treatment separated by two wash-out periods of 13 days with indacaterol 150 μg or matching placebo and tiotropium 18 μg. Lung function was assessed by body plethysmography and spirometry. Physical activity was measured for one week by a multisensory armband at the end of both treatment periods with indacaterol-matched placebo. The primary endpoint was peak inspiratory capacity at the end of each treatment period.

Results129 patients mean age, 61 years; mean post-bronchodilator FEV1, 64%, were randomized and 110 patients completed the study. Peak inspiratory capacity was 0.22 L greater with Indacaterol at day 21 compared to placebo p < 0.001. Similar results were observed for tiotropium. Both bronchodilators also significantly improved other parameters of lung hyperinflation compared with placebo. All parameters of physical activity were significantly increased during treatment with indacaterol versus placebo.

ConclusionsIndacaterol 150 μg improved lung hyperinflation in patients with moderate COPD, which was associated with an increase of physical activity.

Trial registrationClinicalTrials.gov registration number: NCT01012765.

KeywordsChronic obstructive pulmonary disease Lung hyperinflation Bronchodilator treatment Physical activity Electronic supplementary materialThe online version of this article doi:10.1186-1471-2466-14-158 contains supplementary material, which is available to authorized users.

Henrik Watz, Felix Krippner contributed equally to this work.

Download fulltext PDF



Author: Henrik Watz - Felix Krippner - Anne Kirsten - Helgo Magnussen - Claus Vogelmeier

Source: https://link.springer.com/







Related documents